Announcement PDF Distinguished Urological Expert Appointed to LTR Pharma's Scientific Advisory Board 21 May 2025 Highlights • • • Prominent urologist and ED specialist A/Prof. Darren Katz joins LTR Pharma's Scientific Advisory Board Immediate Past Leader of the Australasian Andrology Special Advisory Group (USANZ) brings deep clinical expertise to advance SPONTAN® and ROXUS® Appointment boosts clinical capabilities and strengthens LTR Pharma’s expanding prescriber networks LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that Clinical Associate Professor Darren Katz (A/Prof. Katz), a renowned urological surgeon and Medical Director of Men's Health Melbourne, has joined LTR Pharma's Scientific Advisory Board (“SAB”). As a LTR Pharma's SAB member, A/Prof. Katz will advise the company on its research and development (“R&D”) and clinical development activities for SPONTAN® and ROXUS®, its innovative nasal spray treatments for erectile dysfunction. A/Prof. Katz is a Clinical Associate Professor in the Department of Surgery at the University of Melbourne and the Immediate Past Leader of the Andrology Special Advisory Group to the Urological Society of Australia and New Zealand – a position he held for 6 years. He directs Australia's only Prosthetic and Microsurgical Fellowship, which attracts international urologists for advanced training, and serves as Medical Director of Men's Health Melbourne. He is also a member of an Expert Clinical Advisory Group in the Department of Health in the Australian Government. As a leader in the field of men's health, A/Prof. Katz has extensive expertise in erectile dysfunction, male voiding dysfunction, urological prosthetics, reconstructive urology, and male infertility. He completed his specialist urological training with the Royal Australasian College of Surgeons and spent two years at world-leading hospitals in New York, including Memorial Sloan-Kettering Cancer Centre and Weill-Cornell Medical Centre, where he completed sub-speciality urological fellowships. A/Prof. Katz's extensive clinical experience, prolific academic contributions, including numerous peer-reviewed publications and presentations at major international conferences, and deep understanding of prescriber and patient needs will accelerate LTR Pharma's commercialisation strategy. As part of his role, A/Prof. Katz will serve as an expert consultant specifically for SPONTAN, currently available in Australia through the TGA's Special Access Scheme and Authorised Prescriber Program and will be instrumental in engaging with fellow international key opinion leaders and expanding prescriber networks. His expert commentary is highly sought after in media and has been featured in multiple TV, radio and print media outlets. 1800 519 711 | ltrpharma.com | info@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569) Professor Darren Katz, said: "I am excited to join LTR Pharma's Scientific Advisory Board at this pivotal time for the Company. SPONTAN and ROXUS represent a potentially significant advancement in erectile dysfunction treatment with their rapid onset of action and safety profile. Having worked extensively with patients experiencing erectile dysfunction, I recognise the need for innovative treatments that offer greater spontaneity and fewer side effects. I look forward to contributing to LTR Pharma's mission to improve men's health through this novel approach to ED treatment.” LTR Pharma Executive Chairman, Lee Rodne, said: “We are delighted to welcome Associate Professor Katz to LTR Pharma's Scientific Advisory Board. His extensive clinical experience in men's health and erectile dysfunction will provide invaluable guidance as we advance the development and commercialisation of SPONTAN and ROXUS. Associate Professor Katz's deep expertise in urological health, his vast international connections and his respected position within the medical community will be instrumental in our mission to address the significant unmet need for a fast-acting, on-demand erectile dysfunction treatment.” - ENDS – This announcement has been approved by the Board of Directors. 1800 519 711 | ltrpharma.com | info@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569) About LTR Pharma LTR Pharma is an emerging pharmaceutical company committed to developing and commercialising innovative therapies that address significant unmet medical needs. The Company is leveraging its proprietary intranasal drug delivery platform to enable rapid, non-invasive treatment options across multiple therapeutic areas. LTR’s lead products, SPONTAN® and ROXUS®, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing OROFLOW®, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function. Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life. For further information please contact: Media enquiries Haley Chartres haley@hck.digital Investor enquiries Peter McLennan investors@ltrpharma.com 1800 519 711 | ltrpharma.com | info@ltrpharma.com LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)